JOHNSON & JOHNSON
For the period ended Dec 29, 2024. Filed Feb 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 13, 2025
JNJ$282.11+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated balance sheets
Johnson & Johnson and subsidiaries consolidated balance sheets
At December 29, 2024 and December 31, 2023
(Dollars in Millions Except Share and Per Share Amounts) (Note 1)
| 2024 | 2023 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents (Notes 1 and 2) | $24,105 | 21,859 |
| Marketable securities (Notes 1 and 2) | 417 | 1,068 |
| Accounts receivable trade, less allowances $167 (2023, $166) | 14,842 | 14,873 |
| Inventories (Notes 1 and 3) | 12,444 | 11,181 |
| Prepaid expenses and other receivables | 4,085 | 4,514 |
| Total current assets | 55,893 | 53,495 |
| Property, plant and equipment, net (Notes 1 and 4) | 20,518 | 19,898 |
| Intangible assets, net (Notes 1 and 5) | 37,618 | 34,175 |
| Goodwill (Notes 1 and 5) | 44,200 | 36,558 |
| Deferred taxes on income (Note 8) | 10,461 | 9,279 |
| Other assets | 11,414 | 14,153 |
| Total assets | $180,104 | 167,558 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities | ||
| Loans and notes payable (Note 7) | $5,983 | 3,451 |
| Accounts payable | 10,311 | 9,632 |
| Accrued liabilities | 8,549 | 10,212 |
| Accrued rebates, returns and promotions | 17,580 | 16,001 |
| Accrued compensation and employee related obligations | 4,126 | 3,993 |
| Accrued taxes on income (Note 8) | 3,772 | 2,993 |
| Total current liabilities | 50,321 | 46,282 |
| Long-term debt (Note 7) | 30,651 | 25,881 |
| Deferred taxes on income (Note 8) | 2,448 | 3,193 |
| Employee related obligations (Notes 9 and 10) | 7,255 | 7,149 |
| Long-term taxes payable (Note 1) | 390 | 2,881 |
| Other liabilities | 17,549 | 13,398 |
| Total liabilities | 108,614 | 98,784 |
| Commitments and Contingencies (Note 19) | ||
| Shareholders’ equity | ||
| Preferred stock — without par value (authorized and unissued 2,000,000 shares) | — | — |
| Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) | 3,120 | 3,120 |
| Accumulated other comprehensive income (loss) (Note 13) | (11,741) | (12,527) |
| Retained earnings and Additional-paid-in-capital | 155,791 | 153,843 |
| Less: common stock held in treasury, at cost (Note 12) (712,921,000 shares and 712,765,000 shares) | 75,680 | 75,662 |
| Total shareholders’ equity | 71,490 | 68,774 |
| Total liabilities and shareholders’ equity | $180,104 | 167,558 |
44
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.